Daraxonrasib, a pan-RAS inhibitor, produced a major survival signal in the phase III RASolute-302 trial in second-line metastatic pancreatic ductal adenocarcinoma. The study reported that daraxonrasib more than doubled median overall survival versus chemotherapy in the targeted setting. The finding adds to the growing momentum for RAS-pathway targeted approaches in a disease area where post-progression outcomes remain poor and incremental advances have been difficult to replicate across trials.